Lexeo Therapeutics, Inc. Common StockLXEONASDAQ
LOADING
|||
Cash Flow Under Pressure
Trending lower, below historical average, strong compound growth.
Left:
||||
Operating cash flow minus capital expenditures
Latest
$-81.63M
↓ 67% below average
Average (4y)
$-48.85M
Historical baseline
Range
High:$-3.13M
Low:$-81.63M
CAGR
+125.9%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | $-81.63M | -36.8% |
| 2023 | $-59.66M | -7.6% |
| 2022 | $-55.46M | -25.0% |
| 2021 | $-44.37M | -1316.0% |
| 2020 | $-3.13M | - |